ATNM — Actinium Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $31.06m
- -$11.06m
- $0.09m
Brief: Actinium Announces Nih Grant Extension To Advance Clinical Development Of Cd45 Targeted Conditioning Agent Iomab-Act With Memorial Sloan Kettering's Car-T Cell Therapy
U.S. RESEARCH ROUNDUP- Amgen, FedEx, Zscaler
Brief: Actinium Pharmaceuticals Inc Files For Mixed Shelf Of Up To $500 Million- SEC Filing
Brief: Actinium Announces Positive Pivotal Phase 3 Sierra Trial Results
Brief: Actinium Highlights Successful Administration Of Targeted Radiotherapy Iomab-B Across Various Bmt Centers With Ease And Without Increasing Radiation Exposure Risks To Treating Nursing Staff In The Pivotal Phase 3 Sierra Trial At The 48Th Annual Oncology Nursing Society (Ons) Congress
Brief: Actinium Announces Positive Pivotal Phase 3 Sierra Trial Results Of Iomab-B
Brief: Actinium Highlights First-In-Class Her3 Targeted Radiotherapy Data Demonstrating Potent Anti-Cancer Activity Of In Ovarian And Colorectal Cancer Models At The AACR Annual Meeting
Brief: Actinium Pharmaceuticals Reports 2022 Financial Results
Brief: Actinium Pharmaceuticals Inc - Does Not Hold Any Deposits Or Securities Or Maintain Any Accounts At Silicon Valley Bank
Brief: Actinium Pharmaceuticals Announces Dr. Sergio Giralt To Discuss Positive Results From The Pivotal Phase 3 Sierra Trial Of Iomab-B Via Kol Webinar
Brief: Actinium Announces Positive Full Data Results From The Pivotal Phase 3 Sierra Trial Of Iomab-B
Brief: Actinium To Present Full Results From Pivotal Phase 3 Iomab-B Sierra Trial On Investor Call Following The Late-Breaker Presentation At The 2023 Transplantation & Cellular Therapy Tandem Meetings On Saturday, February 18, 2023
Brief: Actinium Signs Research And Development Agreement With National Cancer Institute For Blood Cancer Treatment
Brief: Actinium Pharmaceuticals Inc Announces Phase 3 Iomab-B Sierra Data Accepted For Late-Breaker Presentation At The Transplantation & Cellular Therapy Tandem Meetings
Brief: Actinium Highlights Survival Data In Relapsed/Refractory AML Patients
Brief: Actinium Pharmaceuticals Announces Research Collaboration With Columbia University
Brief: Actinium Announces Data From Phase 1 Actimab-A Clag-M Combination Trial
Actinium soars as blood cancer therapy meets trial main goal
Brief: Actinium Announces Positive Results From Late-Stage Trial For Acute Myeloid Leukemia Therapy